Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
P.M. Ridker, C.H. Hennekens, J.E. Buring, N. Rifai.
C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women.
N Engl J Med, 342 (2000), pp. 836-843
[2.]
W. Koenig, M. Sund, M. Frohlich, et al.
C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-age men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992.
Circulation, 99 (1999), pp. 237-242
[3.]
J. Danesh, P. Whincup, M. Walker, L. Lennon, A. Thomson, P. Appleby, et al.
Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses.
BMJ, 321 (2000), pp. 199-204
[4.]
P.M. Ridker, N. Rifai, S.P. Lowenthal.
Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia.
Circulation, 103 (2001), pp. 1191-1193
[6.]
A.M. Garber.
Using cost-effectiveness analysis to target cholesterol reduction.
Ann Intern Med, 132 (2000), pp. 833-835
[7.]
C.P. Sparrow, C.A. Burton, M. Hernández, S. Murd, H. Hassing, S. Patel, et al.
Simvastatin has antiinflammatory and antiatherosclerotic activities independent of plasma cholesterol lowering.
Arterioscler Thromb Vasc Biol, 103;21 (2001), pp. 115-121
[8.]
J.J. Escolar Castellón.
Isoprenoides, inflamación y aterosclerosis.
Clin Invest Arterioscl, 12 (2000), pp. 167-170
[9.]
I. Jialal, D. Stein, D. Balis, S.M. Grundy, B. Adams-Huet, S. Devaraj.
Effect of hydroxymethyl glutaryl coenzyme A reductasa inhibitor therapy on high sensitive C-reactive protein levels.
Circulation, 103 (2001), pp. 1933-1935
Copyright © 2002. Sociedad Española de Arteriosclerosis y Elsevier España, S.L.